Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
This invention is directed to indolone derivatives which are antagonists for the GALR3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier.
1. A compound having the structure:
wherein each of Y 1 , Y 2 , Y 3 , and Y 4 is independently —H; straight chained or branched C 1 –C 7 alkyl, —CF 3 , —F, —Cl, —Br, —I, —OR 4 , —N(R 4 ) 2 or —CON(R 4 ) 2 ;
wherein each R 4 is independently —H; straight chained or branched C 1 –C 7 alkyl, monfluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 –C 7 alkenyl or alkynyl; C 3 –C 7 cycloalkyl, C 5 –C 7 cycloalkenyl, aryl or aryl(C 1 –C 6 ) alkyl;
wherein B is aryl;
wherein A is aryl, substituted with —OH; or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 , wherein each of Y 1 , Y 2 , Y 3 and Y 4 is independently H or —OR 4 .
3. The compound of claim 2 , wherein A is naphthyl substituted with —OH.
4. The compound of claim 2 , wherein A is phenyl substituted with —OH.
5. A compound having the following structure:
6. A pure Z imine isomer of the compound of claim 1 .
7. A pure E imine isomer of the compound of claim 1 .
8. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 and a pharmaceutically acceptable carrier.
9. A process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of claim 1 and a pharmaceutically acceptable carrier.
10. A method of treating a subject suffering from depressioh which comprises administering to the subject an amount of the compound of claim 1 effective to treat the subject.
11. A method of treating a subject suffering from anxiety which comprises administering to the subject an amount of the compound of claim 1 effective to treat the subject.
12. A method of treating a subject suffering from depression and anxiety which comprises administering to the subject an amount of the compound of claim 1 effective to treat the subject.
13. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 5 and a pharmaceutically acceptable carrier.
14. A process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of claim 5 and a pharmaceutically acceptable carrier.
15. A method of treating a subject suffering from depression which comprises administering to the subject an amount of the compound of claim 5 effective to treat the subject.
16. A method of treating a subject suffering from anxiety which comprises administering to the subject an amount of the compound of claim 5 effective to treat the subject.
17. A method of treating a subject suffering from depression and anxiety which comprises administering to the subject an amount of the compound of claim 5 effective to treat the subject.